| | Another ARB Gains Approval for Pediatric HypertensionOlmesartan was approved in February for treating hypertension in young people aged 6–16 years, based on a study of 302 children and adolescents. PII: S1544-8800(10)70086-5 doi:10.1016/S1544-8800(10)70086-5 © 2010 Elsevier Inc. All rights reserved. | |
|
|